Noteworthy

Sep 04, 2017
Lisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Sep 04, 2017
Jeremy Schafer & Deborah Lotterman discuss the impact of financial toxicity on patients and payers and outline the strategies needed to begin to remedy it.
Sep 04, 2017
As regulators lower evidentiary requirements for approval to speed development/review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. How can companies can navigate these complexities?
Aug 28, 2017
The federal Open Payments program is finally reaching its goal—to halt the adoption of multiple “transparency” initiatives. But will it make a difference, asks Jill Wechsler.
Aug 25, 2017
Pharmaceutical Executive
Experts assess the current pharma dealmaking landscape—one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.
Aug 21, 2017
Pharmaceutical Executive
Four strategic takeaways from this year's event that are important for pharma oncology leaders, by Maria Whitman and Sharon Karlsberg.
Aug 09, 2017
Pharmaceutical Executive
Pharm Exec’s 13th Annual Press Audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.
Aug 07, 2017
The significance of real-world data has been not utilized to the full potential, writes Uttam Barick.
Aug 07, 2017
Jill Wechsler on the Senate's 94-1 vote to approve legislation reauthorizing user fees and a series of program changes to maintain a smoothly functioning FDA product review and approval process.
Aug 06, 2017
Female students pursuing a Science, Technology, Engineering, and Mathematics (STEM) pathway need earlier enticement and more C-suite role models, writes Mylan’s Head of Global Commercial Development, Adele Gulfo.
native1_300x100
lorem ipsum